Open AccessEndocrine approach in the treatment of obesity: Is there any space for the adiponectin action?
Author(s) -
Konstantinos G. Michalakis
Publication year - 2020
Publication title -
endocrine regulations
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 32
eISSN - 1336-0329
pISSN - 1210-0668
DOI - 10.2478/enr-2020-0018
Subject(s) - adiponectin , adipose tissue , endocrine system , obesity , endocrinology , medicine , hormone , adipokine , helpfulness , insulin resistance , psychology , social psychology
Adiponectin is a hormone secreted by adipose tissue, exerting many positive effects in the human body. Its action has been widely studied, placing it into the metabolic health beneficial products of the adipose tissue. Nevertheless, adiponectin has been shown to exert some extra beneficial non metabolic actions, as well. Adiponectin levels can be related to reduced incidence of cancer in obese patients. Moreover, adiponectin has been shown to be implicated in the positive fertility outcomes of women. Some new studies have also indicated that adiponectin has a potential effect in the control of appetite, which raises a question, whether adiponectin could be accredited to be useful in the endocrine evaluation of obesity. Could these additional non-metabolic actions prove its helpfulness?